BioNTech’s Oncology Drive Gains Momentum with Key Data and Analyst Backing

Positive clinical results for a late-stage cancer drug candidate have strengthened BioNTech’s strategic pivot away from its pandemic-era business. The company presented Phase 2 data for its antibody-drug conjugate BNT323/DB-1303 at a major oncology conference over the weekend, paving the way for a planned regulatory submission to the U.S. Food and Drug Administration (FDA) before year-end.

The data showed a confirmed objective response rate of 47.9% in patients with HER2-expressing, recurrent endometrial cancer whose disease had progressed after first-line chemotherapy. Notably, the response rate was consistent at 49.3% in patients who had previously received checkpoint inhibitor therapy. The median progression-free survival was 8.1 months, with a median duration of response of 10.3 months. BioNTech and its partner DualityBio intend to file a Biologics License Application (BLA) with the FDA based on these results, while a global Phase 3 confirmatory trial is already underway.

This regulatory milestone is central to the company’s broader transformation. BioNTech is actively shifting resources toward its oncology pipeline, a move underscored by the recent decision to close its mRNA vaccine manufacturing facility in Singapore’s Tuas district by February 2027. The site, acquired from Novartis less than four years ago, is being shuttered due to uneconomical operations driven by a steep drop in global demand for pandemic products. The closure affects 85 employees and follows a difficult 2025 financial year that concluded with a net loss exceeding one billion euros.

Should investors sell immediately? Or is it worth buying BioNTech?

The strategic refocusing has garnered cautious support from analysts. Just ahead of the data presentation, Morgan Stanley reaffirmed its “Overweight” rating on BioNTech stock and nudged its price target up slightly from $125 to $126. This adjustment reflects progress within the company’s late-stage oncology portfolio. The broader analyst consensus remains favorable, with an average price target of approximately $131.89 and a majority “Moderate Buy” recommendation. A slight decline in the short interest ratio to 1.73% of free float also suggests a tentative stabilization in institutional sentiment.

With two other candidates, the cancer immunotherapies Gotistobart and Pumitamig, also in Phase III development, BioNTech is aiming to redefine itself as a specialist in antibody-drug conjugates and targeted cancer therapies. The upcoming FDA filing for BNT323/DB-1303 represents a tangible near-term catalyst for this high-stakes transition.